UBS AM’s Accretive Health AH Stock Holding History

UBS AM’s Portfolio AH Stock Details AH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-21,698	Closed	-$199K	–	2609
2013 Q4	$199K	Buy	21,698 +1,100	+5%	+$9.47K	﹤0.01%	2374
2013 Q3	$188K	Hold	20,598	–	–	﹤0.01%	2350
2013 Q2	$223K	Buy	+20,598	New	+$217K	﹤0.01%	2210

Other funds holding AH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JRP

Jasper Ridge Partners Menlo Park, California $4.69B AUM 31.34% 1-Year Est. Return

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

SCA

SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

NTC

North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Amici Capital New York $257M AUM 4.88% 1-Year Est. Return

UBS AM's AH Position: Q1 2014 in Review

UBS AM sold out of Accretive Health (AH) in Q1 2014, closing a stake of 21,698 shares — an estimated $199K sold.

UBS AM first reported a position in AH in Q2 2013 and held it in 3 quarters. The position peaked at $223K in Q2 2013. 66 funds tracked by Wall St. Rank hold AH as of Q1 2014.

UBS AM reported no remaining Accretive Health position as of Q1 2014 after selling out during the quarter.
UBS AM sold 21,698 Accretive Health shares in Q1 2014, an estimated $199K.
UBS AM first reported a position in Accretive Health in Q2 2013 and held it in 3 quarters.
UBS AM's Accretive Health position peaked at $223K in Q2 2013.
66 funds tracked by Wall St. Rank held Accretive Health as of Q1 2014.

Based on UBS AM's 13F filing for Q1 2014, filed 23 May 2014.